Encompass Health has just delivered one of its strongest weeks in recent memory, with a Q2 earnings beat driving a 13% gain in the stock and prompting an immediate wave of upward analyst revisions — a rare instance where the data and the Street move in the same direction at the same time.
The catalyst was unambiguous. EHC reported Q2 results on August 6, and the one-day price reaction came in at roughly 13% — the sharpest single-session move in the earnings history captured here. The stock closed Friday at $125.23, up 12.7% on the week and 13.1% over the past month. The prior note from August 2 flagged bearish options positioning heading into the update; that caution proved entirely misplaced, and the stock now trades at levels that make the previous PCR readings look like noise.
Options positioning has flipped dramatically since the print. The put/call ratio has collapsed to 0.27 — more than 1.2 standard deviations below its 20-day mean of 0.67 — confirming that call demand has surged in the aftermath of the beat. For context, the PCR spent most of July between 0.73 and 1.11, reflecting genuine hedging demand before results. That defensive positioning has been entirely unwound. Borrow conditions remain irrelevant to the story: availability is vast at over 3,699% of short interest, cost to borrow sits at just 0.43%, and short interest itself has eased 5% from Monday to Thursday to 3.7% of free float. There is no squeeze dynamic here, and no meaningful short-side pressure in the lending market.
The Street moved swiftly. Truist Securities raised its target to $150 from $140 on August 7, maintaining its Buy rating. Barclays followed on August 6, lifting its Overweight target to $144 from $140. Both moves came directly in response to the earnings print, and both leave EHC trading at a roughly 14-16% discount to those revised targets, with the consensus mean at $145.25. The bull case — expanding Medicare Advantage mix (now ~16.5% of the payer book versus 9.2% in 2018) and consistently upward-revised revenue guidance — has received fresh validation. The bear case around de novo construction costs and labor market tightness remains live, but this week's print has demonstrably pushed the balance of analyst opinion further in the bullish direction. At a trailing P/E near 19.7x and EV/EBITDA around 11x, the multiple has expanded materially — the EV/EBITDA reading has climbed roughly 0.9x over the past 30 days — though neither figure looks stretched for a company demonstrating this earnings trajectory.
Peers had a notably quieter week. ENSG and HCA each added roughly 2.7% over the same period, while NHC fell 4.6% and PNTG dropped 3.3%. EHC's 13% move stands well apart from the healthcare facilities peer group — the gap is too wide to attribute to sector tailwinds alone, reinforcing that this was a company-specific earnings story rather than a broad-based rotation.
The next scheduled earnings event is October 30. Between now and then, the key variables to track are whether short sellers — who modestly rebuilt positions through late July before this week's partial unwind — continue to reduce exposure as the stock consolidates near post-print levels, and whether analysts with older or more conservative targets begin to close the gap with Truist and Barclays.
See the live data behind this article on ORTEX.
Open EHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
